Trial Profile
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: Epidermal Growth Factor Receptor mutated Non Small Cell Lung Cancer Progressed on Osimertinib arm.
- 06 Jul 2022 Status changed from active, no longer recruiting to completed.
- 25 Feb 2022 Planned End Date changed from 1 Sep 2022 to 31 Dec 2022.